|
Canada-0-FENCING Azienda Directories
|
Azienda News:
- Home - AnaptysBio
AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation
- About - AnaptysBio
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases Its biopharma operations include ANB033, a CD122 antagonist for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter for rheumatoid arthritis; and ANB101, a BDCA2 modulator Anaptys has also discovered and out
- Pipeline - AnaptysBio
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need
- Anaptys Provides Update on Business Separation and Announces Fourth . . .
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today provided an update on the potential spin-off of its biopharma operations and reported financial results for the fourth quarter and year ended Dec 31, 2025
- Science - AnaptysBio
Immune cell modulators (ICM) are a novel therapeutic class with the potential to treat autoimmune and inflammatory diseases across a broad range of therapeutic areas, including rheumatology, gastroenterology, respiratory, dermatology and neurology Anaptys’ ICMs are engineered to have a top-down, broad impact on the most pathogenic cells driving disease by targeting specific activated immune
- Presentations Events - AnaptysBio, Inc.
The Investor Relations website contains information about AnaptysBio, Inc 's business for stockholders, potential investors, and financial analysts
- News - AnaptysBio, Inc.
The Investor Relations website contains information about AnaptysBio, Inc 's business for stockholders, potential investors, and financial analysts
- AnaptysBio, Inc.
AnaptysBio, Inc
- Anaptys Announces Intent to Separate Biopharma Operations from . . .
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
- Anaptys Announces Second Quarter 2025 Financial Results and Provides . . .
SAN DIEGO, Aug 06, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update
|
|